Expertise in
13
conditions

Odile Launay

Paris, FR 
Expertise in
13
conditions
Paris, FR 

Overview

Odile Launay practices practicing medicine in Paris, France.

Ms. Launay is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Flu, COVID-19, Parainfluenza, Yellow Fever, and Liver Transplant.

She is actively involved in clinical research, co-authoring 319 peer reviewed articles and participating in 8 clinical trials.

Gender

Female

Locations

Paris, France
Other Locations
Creteil, France
Saint-etienne-de-valoux, France
Saint-claude-de-diray, France
France
27, Rue Du Faubourg Saint Jacques 75014 Paris, Saint-jacques-d'atticieux, 75014, France
59, Boulevard Pinel, Bron, 69677, France
55, Avenue De Paris, Versailles, 78280, France
59, Boulevard Pinel, Lyon, 69003, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Other, Drug
Study Drugs: Remdesivir, Lopinavir, Ritonavir, Interferon Beta-1A, Hydroxychloroquine, AZD7442
Study Phase: Phase 3
A Descriptive, Prospective, Multi-country, Multicentre Study to Assess Performance of Genital Herpes Simplex Virus-2 (HSV-2) Related Disease Endpoints Based on Patient-reported Health Outcomes, Self-swabbing Collected Via Decentralised Approach in Patients ≥ 18 Years of Age in the United States and Europe.
A Descriptive, Prospective, Multi-country, Multicentre Study to Assess Performance of Genital Herpes Simplex Virus-2 (HSV-2) Related Disease Endpoints Based on Patient-reported Health Outcomes, Self-swabbing Collected Via Decentralised Approach in Patients ≥ 18 Years of Age in the United States and Europe.
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Procedure
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
Immunogenicity and Safety Study of GSK's Investigational Vaccine (GSK3277511A) When Administered in Healthy Smokers and Ex-smokers Following Receipt of Shingrix Vaccine
Immunogenicity and Safety Study of GSK's Investigational Vaccine (GSK3277511A) When Administered in Healthy Smokers and Ex-smokers Following Receipt of Shingrix Vaccine
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Biological
Study Phase: Phase 2
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Biological
Study Drugs: Prevenar 13, Pneumo 23
Study Phase: Phase 2
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
Enrollment Status: Completed
Publish Date: December 13, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
ANRS RF002 Intestipax : Interleukin-23 (IL-23)/Interleukin-12 (IL-12) Imbalance and T Lymphocyte Polarization in HIV Infection
ANRS RF002 Intestipax : Interleukin-23 (IL-23)/Interleukin-12 (IL-12) Imbalance and T Lymphocyte Polarization in HIV Infection
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Other
Study Phase: Not Applicable
Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
Enrollment Status: Terminated
Publish Date: June 01, 2017
View 7 Less Clinical Trials

319 Total Publications

Association between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16-2024/25.
Association between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16-2024/25.
Journal: Expert review of vaccines
Published: August 27, 2026

Frequently Asked Questions about Odile Launay

Is Odile Launay a top-rated expert for Flu?

MediFind is an objective health platform that identifies experts based on real-world data. Odile Launay is classified as an Elite expert for Flu, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Odile Launay participate in research or clinical trials?

Yes. Odile Launay has published 319 articles and abstracts on conditions like Flu. You can view a list of Odile Launay's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Launay's expertise for a condition
ConditionClose
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile